157 related articles for article (PubMed ID: 20472115)
1. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously.
Segall-Gutierrez P; Taylor D; Liu X; Stanzcyk F; Azen S; Mishell DR
Contraception; 2010 Jun; 81(6):487-95. PubMed ID: 20472115
[TBL] [Abstract][Full Text] [Related]
2. Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women.
Segall-Gutierrez P; Du J; Niu C; Ge M; Tilley I; Mizraji K; Stanczyk FZ
Contraception; 2012 Dec; 86(6):739-45. PubMed ID: 22959905
[TBL] [Abstract][Full Text] [Related]
3. A pilot study examining short-term changes in bone mineral density among class 3 obese users of depot-medroxyprogesterone acetate.
Segall-Gutierrez P; Agarwal R; Ge M; Lopez C; Hernandez G; Stanczyk FZ
Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):199-205. PubMed ID: 23530919
[TBL] [Abstract][Full Text] [Related]
4. Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use.
Segall-Gutierrez P; Xiang AH; Watanabe RM; Trigo E; Stanczyk FZ; Liu X; Jurow R; Buchanan TA
Contraception; 2012 Jan; 85(1):36-41. PubMed ID: 22067800
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics and pharmacodynamics after subcutaneous and intramuscular administration of medroxyprogesterone acetate (25 mg) and estradiol cypionate (5 mg).
Sierra-Ramírez JA; Lara-Ricalde R; Lujan M; Velázquez-Ramírez N; Godínez-Victoria M; Hernádez-Munguía IA; Padilla A; Garza-Flores J
Contraception; 2011 Dec; 84(6):565-70. PubMed ID: 22078184
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of depot medroxyprogesterone acetate contraception.
Mishell DR
J Reprod Med; 1996 May; 41(5 Suppl):381-90. PubMed ID: 8725700
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
[TBL] [Abstract][Full Text] [Related]
8. Contraceptive efficacy and safety of DMPA-SC.
Jain J; Jakimiuk AJ; Bode FR; Ross D; Kaunitz AM
Contraception; 2004 Oct; 70(4):269-75. PubMed ID: 15451329
[TBL] [Abstract][Full Text] [Related]
9. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
10. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics.
Rahimy MH; Cromie MA; Hopkins NK; Tong DM
Contraception; 1999 Oct; 60(4):201-8. PubMed ID: 10640166
[TBL] [Abstract][Full Text] [Related]
11. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles.
Westhoff CL; Reinecke I; Bangerter K; Merz M
Contraception; 2014 Sep; 90(3):272-9. PubMed ID: 24969733
[TBL] [Abstract][Full Text] [Related]
12. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL.
Westhoff C; Jain JK; Milsom I; Ray A
Contraception; 2007 Apr; 75(4):261-7. PubMed ID: 17362703
[TBL] [Abstract][Full Text] [Related]
13. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women.
Toh YC; Jain J; Rahnny MH; Bode FR; Ross D
Clin Ther; 2004 Nov; 26(11):1845-54. PubMed ID: 15639696
[TBL] [Abstract][Full Text] [Related]
14. Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics.
Thurman A; Kimble T; Hall P; Schwartz JL; Archer DF
Contraception; 2013 Jun; 87(6):738-43. PubMed ID: 23265980
[TBL] [Abstract][Full Text] [Related]
15. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive.
Pantoja M; Medeiros T; Baccarin MC; Morais SS; Bahamondes L; Fernandes AM
Contraception; 2010 Feb; 81(2):107-11. PubMed ID: 20103446
[TBL] [Abstract][Full Text] [Related]
16. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women.
Rahimy MH; Ryan KK
Contraception; 1999 Oct; 60(4):189-200. PubMed ID: 10640165
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera.
Jain J; Dutton C; Nicosia A; Wajszczuk C; Bode FR; Mishell DR
Contraception; 2004 Jul; 70(1):11-8. PubMed ID: 15208047
[TBL] [Abstract][Full Text] [Related]
18. Return of ovulation following a single injection of depo-medroxyprogesterone acetate: a pharmacokinetic and pharmacodynamic study.
Lan PT; Aedo AR; Landgren BM; Johannisson E; Diczfalusy E
Contraception; 1984 Jan; 29(1):1-18. PubMed ID: 6234145
[TBL] [Abstract][Full Text] [Related]
19. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
Picardo C; Ferreri S
Contraception; 2010 Aug; 82(2):160-7. PubMed ID: 20654757
[TBL] [Abstract][Full Text] [Related]
20. Delayed first injection of the once-a-month injectable contraceptive containing 25 mg of medroxyprogesterone acetate and 5 mg of E(2)-cypionate: effects on ovarian function.
Petta CA; Hays M; Brache V; Massai R; Hua Y; Alvarez-Sánchez F; Croxatto H; d'Arcangues C; Cook LA; Bahamondes L
Fertil Steril; 2001 Apr; 75(4):744-8. PubMed ID: 11287029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
